The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration

Jennifer M. Deger, Julia E. Gerson, Rakez Kayed

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Various neurodegenerative diseases are characterized by the accumulation of amyloidogenic proteins such as tau, α-synuclein, and amyloid-β. Prior to the formation of these stable aggregates, intermediate species of the respective proteins-oligomers-appear. Recently acquired data have shown that oligomers may be the most toxic and pathologically significant to neurodegenerative diseases such as Alzheimer's and Parkinson's. The covalent modification of these oligomers may be critically important for biological processes in disease. Ubiquitin and small ubiquitin-like modifiers are the commonly used tags for degradation. While the modification of large amyloid aggregates by ubiquitination is well established, very little is known about the role ubiquitin may play in oligomer processing and the importance of the more recently discovered sumoylation. Many proteins involved in neurodegeneration have been found to be sumoylated, notably tau protein in brains afflicted with Alzheimer's. This evidence suggests that while the cell may not have difficulty recognizing dangerous proteins, in brains afflicted with neurodegenerative disease, the proteasome may be unable to properly digest the tagged proteins. This would allow toxic aggregates to develop, leading to even more proteasome impairment in a snowball effect that could explain the exponential progression in most neurodegenerative diseases. A better understanding of the covalent modifications of oligomers could have a huge impact on the development of therapeutics for neurodegenerative diseases. This review will focus on the proteolysis of tau and other amyloidogenic proteins induced by covalent modification, and recent findings suggesting a relationship between tau oligomers and sumoylation.

Original languageEnglish (US)
Pages (from-to)715-724
Number of pages10
JournalAging Cell
Volume14
Issue number5
DOIs
StatePublished - Oct 1 2015

Fingerprint

Proteasome Endopeptidase Complex
Neurodegenerative Diseases
Ubiquitin
Sumoylation
Amyloidogenic Proteins
Poisons
Amyloid
Proteins
Synucleins
Biological Phenomena
tau Proteins
Ubiquitination
Brain
Proteolysis

Keywords

  • Alzheimer's disease
  • Covalent modification
  • Huntington's disease
  • Neurodegeneration
  • Parkinson's disease
  • Small ubiquitin-like modifiers
  • Tau oligomers
  • Tauopathies
  • Ubiquitin proteasome system
  • Ubiquitination

ASJC Scopus subject areas

  • Cell Biology
  • Aging

Cite this

The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration. / Deger, Jennifer M.; Gerson, Julia E.; Kayed, Rakez.

In: Aging Cell, Vol. 14, No. 5, 01.10.2015, p. 715-724.

Research output: Contribution to journalArticle

Deger, Jennifer M. ; Gerson, Julia E. ; Kayed, Rakez. / The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration. In: Aging Cell. 2015 ; Vol. 14, No. 5. pp. 715-724.
@article{84eacbcc302c4d2baa438351bcdb8b69,
title = "The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration",
abstract = "Various neurodegenerative diseases are characterized by the accumulation of amyloidogenic proteins such as tau, α-synuclein, and amyloid-β. Prior to the formation of these stable aggregates, intermediate species of the respective proteins-oligomers-appear. Recently acquired data have shown that oligomers may be the most toxic and pathologically significant to neurodegenerative diseases such as Alzheimer's and Parkinson's. The covalent modification of these oligomers may be critically important for biological processes in disease. Ubiquitin and small ubiquitin-like modifiers are the commonly used tags for degradation. While the modification of large amyloid aggregates by ubiquitination is well established, very little is known about the role ubiquitin may play in oligomer processing and the importance of the more recently discovered sumoylation. Many proteins involved in neurodegeneration have been found to be sumoylated, notably tau protein in brains afflicted with Alzheimer's. This evidence suggests that while the cell may not have difficulty recognizing dangerous proteins, in brains afflicted with neurodegenerative disease, the proteasome may be unable to properly digest the tagged proteins. This would allow toxic aggregates to develop, leading to even more proteasome impairment in a snowball effect that could explain the exponential progression in most neurodegenerative diseases. A better understanding of the covalent modifications of oligomers could have a huge impact on the development of therapeutics for neurodegenerative diseases. This review will focus on the proteolysis of tau and other amyloidogenic proteins induced by covalent modification, and recent findings suggesting a relationship between tau oligomers and sumoylation.",
keywords = "Alzheimer's disease, Covalent modification, Huntington's disease, Neurodegeneration, Parkinson's disease, Small ubiquitin-like modifiers, Tau oligomers, Tauopathies, Ubiquitin proteasome system, Ubiquitination",
author = "Deger, {Jennifer M.} and Gerson, {Julia E.} and Rakez Kayed",
year = "2015",
month = "10",
day = "1",
doi = "10.1111/acel.12359",
language = "English (US)",
volume = "14",
pages = "715--724",
journal = "Aging Cell",
issn = "1474-9718",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration

AU - Deger, Jennifer M.

AU - Gerson, Julia E.

AU - Kayed, Rakez

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Various neurodegenerative diseases are characterized by the accumulation of amyloidogenic proteins such as tau, α-synuclein, and amyloid-β. Prior to the formation of these stable aggregates, intermediate species of the respective proteins-oligomers-appear. Recently acquired data have shown that oligomers may be the most toxic and pathologically significant to neurodegenerative diseases such as Alzheimer's and Parkinson's. The covalent modification of these oligomers may be critically important for biological processes in disease. Ubiquitin and small ubiquitin-like modifiers are the commonly used tags for degradation. While the modification of large amyloid aggregates by ubiquitination is well established, very little is known about the role ubiquitin may play in oligomer processing and the importance of the more recently discovered sumoylation. Many proteins involved in neurodegeneration have been found to be sumoylated, notably tau protein in brains afflicted with Alzheimer's. This evidence suggests that while the cell may not have difficulty recognizing dangerous proteins, in brains afflicted with neurodegenerative disease, the proteasome may be unable to properly digest the tagged proteins. This would allow toxic aggregates to develop, leading to even more proteasome impairment in a snowball effect that could explain the exponential progression in most neurodegenerative diseases. A better understanding of the covalent modifications of oligomers could have a huge impact on the development of therapeutics for neurodegenerative diseases. This review will focus on the proteolysis of tau and other amyloidogenic proteins induced by covalent modification, and recent findings suggesting a relationship between tau oligomers and sumoylation.

AB - Various neurodegenerative diseases are characterized by the accumulation of amyloidogenic proteins such as tau, α-synuclein, and amyloid-β. Prior to the formation of these stable aggregates, intermediate species of the respective proteins-oligomers-appear. Recently acquired data have shown that oligomers may be the most toxic and pathologically significant to neurodegenerative diseases such as Alzheimer's and Parkinson's. The covalent modification of these oligomers may be critically important for biological processes in disease. Ubiquitin and small ubiquitin-like modifiers are the commonly used tags for degradation. While the modification of large amyloid aggregates by ubiquitination is well established, very little is known about the role ubiquitin may play in oligomer processing and the importance of the more recently discovered sumoylation. Many proteins involved in neurodegeneration have been found to be sumoylated, notably tau protein in brains afflicted with Alzheimer's. This evidence suggests that while the cell may not have difficulty recognizing dangerous proteins, in brains afflicted with neurodegenerative disease, the proteasome may be unable to properly digest the tagged proteins. This would allow toxic aggregates to develop, leading to even more proteasome impairment in a snowball effect that could explain the exponential progression in most neurodegenerative diseases. A better understanding of the covalent modifications of oligomers could have a huge impact on the development of therapeutics for neurodegenerative diseases. This review will focus on the proteolysis of tau and other amyloidogenic proteins induced by covalent modification, and recent findings suggesting a relationship between tau oligomers and sumoylation.

KW - Alzheimer's disease

KW - Covalent modification

KW - Huntington's disease

KW - Neurodegeneration

KW - Parkinson's disease

KW - Small ubiquitin-like modifiers

KW - Tau oligomers

KW - Tauopathies

KW - Ubiquitin proteasome system

KW - Ubiquitination

UR - http://www.scopus.com/inward/record.url?scp=84940895961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940895961&partnerID=8YFLogxK

U2 - 10.1111/acel.12359

DO - 10.1111/acel.12359

M3 - Article

VL - 14

SP - 715

EP - 724

JO - Aging Cell

JF - Aging Cell

SN - 1474-9718

IS - 5

ER -